Neutropenic Sepsis

  • William Thompson
  • Rosalie Stephen
  • Michelle K. WilsonEmail author
Reference work entry


Febrile neutropenia is a common complication of cytotoxic therapies and can be potentially life threatening. Treatment for neutropenic fever has evolved with the advent of antibiotics with mortality rates falling as a consequence. Patterns of infection have changed from being predominantly related to gram-negative organisms to now being mostly caused by gram-positive organisms. However, in the majority of cases, no source is isolated.

Higher rates of febrile neutropenia are seen with cytotoxic treatments for hematological malignancies, compared to that for solid malignancies. Therapies to reduce the risk of febrile neutropenia should be considered in patients at high risk of prolonged (>7 days) and severe (<1 × 109 cells/L) neutropenia and also in those who would poorly tolerate the complication. Risk factors for neutropenic fever include age >65, prior exposure to chemotherapy or radiation, persistent neutropenia, bone marrow involvement by tumor, recent surgery and/or open wounds, renal dysfunction, and liver dysfunction.

Management requires prompt commencement of antibiotics, careful investigations into a possible source, and supportive cares. Empiric antibiotics with an antipseudomonal cephalosporin or a carbopenem should be started early. Data around the synergism of aminoglycosides is unclear. Treatment should be modified dependent on the results of the investigations. In the setting of a persistent fever, the addition of vancomycin and/or an antifungal agent should be considered.

Patients should be well informed of this potential life-threatening complication. Mortality can vary from 1% in low-risk patients to 50% in those requiring ICU admission with septic shock.


  1. Angus DC , van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840–51. Available from: Scholar
  2. Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013;368(12):1131–9.CrossRefGoogle Scholar
  3. Blot F, Nitenberg GE, Chachaty E, Raynard B, Germann N, Antoun S, et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet. 1999;354(9184):1071–7. [cited 2017 Feb 24]. Available from: Scholar
  4. Bodey GP. The treatment of febrile neutropenia: from the dark ages to the present. Support Care Cancer. 1997;5:351–7.CrossRefGoogle Scholar
  5. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64(2):328–40. [cited 2017 Feb 24]. Available from: Scholar
  6. Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977–87. Available from: Scholar
  7. Cometta A, Kern WV, De Bock R, Paesmans M, Vandenbergh M, Crokaert F, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis. 2003;37(3):382–9.CrossRefGoogle Scholar
  8. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 2005;353(10):988–98. [cited 2017 Feb 24]. Available from: Scholar
  9. de Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21(Suppl 5):v252–6.CrossRefGoogle Scholar
  10. Elting LS, Lu C, Escalante CP, Giordano SH, Trent JC, Cooksley C, et al. Outcomes and cost of outpatient or inpatient management of 712 patients with febrile neutropenia. J Clin Oncol. 2008;26(4):606–11.CrossRefGoogle Scholar
  11. Feld R. Bloodstream infections in cancer patients with febrile neutropenia. Int J Antimicrob Agents. 2008;32(Suppl 1):S30–3.CrossRefGoogle Scholar
  12. Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology clinical practice guideline. J Clin Oncol. 2013;31(6):794–810.CrossRefGoogle Scholar
  13. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:427–31.Google Scholar
  14. Gafter-Gvili A, Fraser A, Paul M, Vidal L, Lawrie TA, van de Wetering MD, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane database Syst Rev. 2012;1(1):CD004386. [cited 2017 Feb 24]. Available from:
  15. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100(3):345–51. [cited 2017 Feb 24]. Available from: Scholar
  16. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev. 2014;9:CD000026.Google Scholar
  17. Hengartner H, Berger C, Nadal D, Niggli FK, Grotzer MA. Port-A-Cath infections in children with cancer. Eur J Cancer. 2004;40(16):2452–8. [cited 2017 Feb 24];Available from: Scholar
  18. Innes H, Marshall E. Outpatient therapy for febrile neutropenia. Curr Opin Oncol. 2007;19(4):294–8. Available from:
  19. Innes H, Lim SL, Hall A, Chan SY, Bhalla N, Marshall E. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer. 2008;16(5):485–91.CrossRefGoogle Scholar
  20. Kern WV, Klose K, Jellen-Ritter AS, Oethinger M, Bohnert J, Kern P, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis. 2005;24(2):111–8. [cited 2017 Feb 24]. Available from: Scholar
  21. Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK, et al. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia (Review). Cochrane Database Syst Rev. 2014;24(2). [cited 2017 Feb 24]. Available from:
  22. Klastersky J. Science and pragmatism in the treatment and prevention of neutropenic infection. J Antimicrob Chemother. 1998;41(Suppl D):13–24. [cited 2017 Feb 24]. Available from: Scholar
  23. Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–51. [cited 2017 Feb 24]Available from: Scholar
  24. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258–66.CrossRefGoogle Scholar
  25. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34(6):1589–96. Available from: Scholar
  26. Legrand M, Max A, Peigne V, Mariotte E, Canet E, Debrumetz A, et al. Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med. 2012;40(1):43–9. Available from: Scholar
  27. Mhaskar R, Clark OA, Lyman G, Engel Ayer Botrel T, Morganti Paladini L, Djulbegovic B. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev. 2014;10:CD003039.Google Scholar
  28. NCCN Clinical Practice Guidelines in Oncology™. [cited 2017 Feb 24]. Available from:
  29. Paul M, Dickstein Y, Schlesinger A, Grozinsky-Glasberg S, Soares-Weiser K, Leibovici L. Beta-lactam versus beta-lactam-aminoglycoside combination therapy in cancer patients with neutropenia. Cochrane database Syst Rev. 2013;6(6):CD003038. [cited 2017 Feb 24]. Available from:
  30. Paul M, Dickstein Y, Borok S, Vidal L, Leibovici L. Empirical antibiotics targeting Gram-positive bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane Database Syst Rev. 2014;1(1):CD003914. [cited 2017 Feb 24]. Available from:
  31. Penack O, Becker C, Buchheidt D, Christopeit M, Kiehl M, von Lilienfeld-Toal M, et al. Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). Ann Hematol. 2014;93(7):1083–95. [cited 2017 Feb 24]. Available from: Scholar
  32. Pépin J, Saheb N, Coulombe M-A, Alary M-E, Corriveau M-P, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005;41(9):1254–60. Available from: Scholar
  33. Richardson MD. Antifungal therapy in “bone marrow failure”. Br J Haematol. 1998;100:619–28.CrossRefGoogle Scholar
  34. Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014;58:3799–803.CrossRefGoogle Scholar
  35. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel KWY, Benbenishty J, Kalenka A, Forst H, Laterre PF, Reinhart K, Cuthbertson BH, Payen D, Briegel J, CORTICUS Study Group. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111–24.CrossRefGoogle Scholar
  36. Stein A, Voigt W, Jordan K. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol. 2010;2(1):51–63. Available from:,
  37. Uys A, Rapoport BL, Anderson R, Uys A, Rapoport BL, Anderson R. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer. 2004;12:555–60.CrossRefGoogle Scholar
  38. Vidal L, Ben dor I, Paul M, Eliakim-Raz N, Pokroy E, Soares-Weiser K, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. In: Vidal L, editor. Cochrane database of systematic reviews. Chichester: Wiley; 2013. [cited 2017 Feb 24]. Available from:
  39. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4):225–34.CrossRefGoogle Scholar
  40. Wolf H-H, Leithäuser M, Maschmeyer G, Salwender H, Klein U, Chaberny I, et al. Central venous catheter-related infections in hematology and oncology. Ann Hematol. 2008;87(11):863–76. [cited 2017 Jan 4]. Available from: Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • William Thompson
    • 1
  • Rosalie Stephen
    • 1
  • Michelle K. Wilson
    • 1
    Email author
  1. 1.Cancer and Blood ServicesAuckland City HospitalAucklandNew Zealand

Personalised recommendations